BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20069569)

  • 1. Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations.
    Wang XM; Greiner TC; Bibikova M; Pike BL; Siegmund KD; Sinha UK; Müschen M; Jaeger EB; Weisenburger DD; Chan WC; Shibata D; Fan JB; Hacia JG
    J Cell Biochem; 2010 Mar; 109(4):818-27. PubMed ID: 20069569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status.
    Pike BL; Greiner TC; Wang X; Weisenburger DD; Hsu YH; Renaud G; Wolfsberg TG; Kim M; Weisenberger DJ; Siegmund KD; Ye W; Groshen S; Mehrian-Shai R; Delabie J; Chan WC; Laird PW; Hacia JG
    Leukemia; 2008 May; 22(5):1035-43. PubMed ID: 18288132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma.
    Ferraresso S; Aricò A; Sanavia T; Da Ros S; Milan M; Cascione L; Comazzi S; Martini V; Giantin M; Di Camillo B; Mazzariol S; Giannuzzi D; Marconato L; Aresu L
    Sci Rep; 2017 Sep; 7(1):11591. PubMed ID: 28912427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.
    Zhang YW; Zhang J; Li J; Zhu JF; Yang YL; Zhou LL; Hu ZL; Zhang F
    Leuk Lymphoma; 2015; 56(8):2429-38. PubMed ID: 25487076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.
    Gal-Yam EN; Egger G; Iniguez L; Holster H; Einarsson S; Zhang X; Lin JC; Liang G; Jones PA; Tanay A
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12979-84. PubMed ID: 18753622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
    [No Abstract]   [Full Text] [Related]  

  • 7. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.
    Rinaldi A; Mensah AA; Kwee I; Forconi F; Orlandi EM; Lucioni M; Gattei V; Marasca R; Berger F; Cogliatti S; Cavalli F; Zucca E; Gaidano G; Rossi D; Bertoni F
    Br J Haematol; 2013 Oct; 163(2):194-204. PubMed ID: 23961875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.
    Shaknovich R; Geng H; Johnson NA; Tsikitas L; Cerchietti L; Greally JM; Gascoyne RD; Elemento O; Melnick A
    Blood; 2010 Nov; 116(20):e81-9. PubMed ID: 20610814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
    Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
    J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T; Hussain S; Feldman AL; Galardy PJ
    Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.
    Bertrand P; Maingonnat C; Penther D; Guney S; Ruminy P; Picquenot JM; Mareschal S; Alcantara M; Bouzelfen A; Dubois S; Figeac M; Bastard C; Tilly H; Jardin F
    Genes Chromosomes Cancer; 2013 Aug; 52(8):764-74. PubMed ID: 23716461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Bujisic B; De Gassart A; Tallant R; Demaria O; Zaffalon L; Chelbi S; Gilliet M; Bertoni F; Martinon F
    Blood; 2017 Apr; 129(17):2420-2428. PubMed ID: 28167662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
    Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
    Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
    Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
    Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.
    Bethge N; Honne H; Andresen K; Hilden V; Trøen G; Liestøl K; Holte H; Delabie J; Lind GE; Smeland EB
    PLoS One; 2014; 9(9):e104249. PubMed ID: 25226156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Array-based DNA methylation profiling of primary lymphomas of the central nervous system.
    Richter J; Ammerpohl O; Martín-Subero JI; Montesinos-Rongen M; Bibikova M; Wickham-Garcia E; Wiestler OD; Deckert M; Siebert R
    BMC Cancer; 2009 Dec; 9():455. PubMed ID: 20025734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.